Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Assets: 2021-2025

Historic Current Assets for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $338.9 million.

  • ARS Pharmaceuticals' Current Assets rose 62.30% to $338.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.9 million, marking a year-over-year increase of 62.30%. This contributed to the annual value of $334.3 million for FY2024, which is 44.26% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Current Assets of $338.9 million as of Q3 2025, which was up 20.40% from $281.4 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Current Assets peaked at $378.3 million during Q1 2021, and registered a low of $60.7 million during Q4 2021.
  • For the 3-year period, ARS Pharmaceuticals' Current Assets averaged around $264.8 million, with its median value being $255.0 million (2023).
  • Examining YoY changes over the last 5 years, ARS Pharmaceuticals' Current Assets showed a top increase of 357.27% in 2022 and a maximum decrease of 30.93% in 2022.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Current Assets stood at $60.7 million in 2021, then skyrocketed by 357.27% to $277.7 million in 2022, then declined by 16.56% to $231.7 million in 2023, then soared by 44.26% to $334.3 million in 2024, then skyrocketed by 62.30% to $338.9 million in 2025.
  • Its Current Assets stands at $338.9 million for Q3 2025, versus $281.4 million for Q2 2025 and $303.9 million for Q1 2025.